- Home
- OLMA vs PRTA Comparison
OLMA vs PRTA Comparison
Compare OLMA & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLMA
- PRTA
- Stock Information
- Founded
- OLMA 2006
- PRTA 2012
- Country
- OLMA United States
- PRTA Ireland
- Employees
- OLMA N/A
- PRTA N/A
- Industry
- OLMA Biotechnology: Pharmaceutical Preparations
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- OLMA Health Care
- PRTA Health Care
- Exchange
- OLMA Nasdaq
- PRTA Nasdaq
- Market Cap
- OLMA 299.7M
- PRTA 351.5M
- IPO Year
- OLMA 2020
- PRTA N/A
- Fundamental
- Price
- OLMA $5.33
- PRTA $6.81
- Analyst Decision
- OLMA Strong Buy
- PRTA Buy
- Analyst Count
- OLMA 4
- PRTA 9
- Target Price
- OLMA $24.50
- PRTA $27.67
- AVG Volume (30 Days)
- OLMA 411.5K
- PRTA 795.6K
- Earning Date
- OLMA 08-05-2025
- PRTA 08-04-2025
- Dividend Yield
- OLMA N/A
- PRTA N/A
- EPS Growth
- OLMA N/A
- PRTA N/A
- EPS
- OLMA N/A
- PRTA N/A
- Revenue
- OLMA N/A
- PRTA $137,935,000.00
- Revenue This Year
- OLMA N/A
- PRTA N/A
- Revenue Next Year
- OLMA N/A
- PRTA $122.46
- P/E Ratio
- OLMA N/A
- PRTA N/A
- Revenue Growth
- OLMA N/A
- PRTA 54.55
- 52 Week Low
- OLMA $2.86
- PRTA $4.32
- 52 Week High
- OLMA $16.62
- PRTA $23.66
- Technical
- Relative Strength Index (RSI)
- OLMA 66.85
- PRTA 59.66
- Support Level
- OLMA $4.40
- PRTA $6.74
- Resistance Level
- OLMA $5.36
- PRTA $7.33
- Average True Range (ATR)
- OLMA 0.29
- PRTA 0.32
- MACD
- OLMA 0.07
- PRTA 0.03
- Stochastic Oscillator
- OLMA 93.20
- PRTA 55.56
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.